Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 134

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 8
Chunk 134
---
 income attributable to common stockholders per share of common stock and diluted net income attributable to common stockholders per share of common stock for the three and six months ended June 30, 2025, is as follows (in thousands):Three months endedSix months endedJune 30, 2025Basic net income per share of common stock:Net income$74,707 $71,608 Earnings allocated to participating securities(6,798)(6,552)Net income attributable to shares of common stock67,909 65,056 Less: Dividends declared or accumulated— — Undistributed net income attributable to shares of common stock, basic67,909 65,056 Weighted-average shares of common stock outstanding54,781 54,440 Basic net income per share of common stock$1.24 $1.20 Diluted net income per share of common stock:Net income attributable to shares of common stock67,909 65,056 Less: Fair value adjustment income related to warrant liability— — Net income attributable to shares of common stock, diluted67,909 65,056 Weighted-average number of shares of common stock outstanding54,781 54,440 Dilutive effect of outstanding stock options (as converted to common stock)1,544 1,622 Weighted-average shares of common stock outstanding, diluted56,325 56,062 Diluted net income per share of common stock$1.21 $1.16 

24

K.    LeasesThe Company has operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. The Company determines if an arrangement is a lease at contract inception. Lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company does not separate lease and non-lease components. Leases with a term of 12 months or less at commencement are not recorded on the unaudited condensed consolidated balance sheets. Lease expense for these arrangements is recognized on a straight-line basis over the lease term. The Company’s leases have remaining lease terms of less than 1 year and up to approximately 3 years, some of which include options to extend the leases for up to 5 years, and some which include options to terminate the leases within 1 year.The components of lease expense were as follows (in thousands): Three months ended June